These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36276561)

  • 1. Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data.
    Karakus V; Maral S; Kaya E; Gemici A; Dere Y; Sevindik OG
    North Clin Istanb; 2022; 9(4):331-336. PubMed ID: 36276561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
    Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
    Gershon A; Ma E; Xu T; Montez M; Naqvi K; Ku G; Cheng WW; Flahavan EM; Kota V; Greenwald DR
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e222-e231. PubMed ID: 36925388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
    Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
    Gabellier L; Peterlin P; Thepot S; Hicheri Y; Paul F; Gallego-Hernanz MP; Bertoli S; Turlure P; Pigneux A; Guieze R; Ochmann M; Malfuson JV; Cluzeau T; Thomas X; Tavernier E; Jourdan E; Bonnet S; Tudesq JJ; Raffoux E
    Ann Hematol; 2024 Mar; 103(3):759-769. PubMed ID: 38273140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.
    Zeidan AM; Wang R; Wang X; Shallis RM; Podoltsev NA; Bewersdorf JP; Huntington SF; Neparidze N; Giri S; Gore SD; Davidoff AJ; Ma X
    Blood Adv; 2020 May; 4(10):2192-2201. PubMed ID: 32433746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
    De Bellis E; Imbergamo S; Candoni A; Liço A; Tanasi I; Mauro E; Mosna F; Leoncin M; Stulle M; Griguolo D; Pravato S; Trentin L; Lazzarotto D; Di Bona E; Bassan R; Lucchini E; Poiani M; Palmieri C; Zaja F
    Leuk Res; 2022 Mar; 114():106803. PubMed ID: 35150967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
    Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
    Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
    Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
    Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients With Acute Myeloid Leukemia: A 10-Year Experience.
    Rungjirajittranon T; Kungwankiattichai S; Kunacheewa C; Owattanapanich W
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):852-860. PubMed ID: 34364821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
    Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
    Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.
    Molica M; Mazzone C; Niscola P; Carmosino I; Di Veroli A; De Gregoris C; Bonanni F; Perrone S; Cenfra N; Fianchi L; Piccioni AL; Spadea A; Luzi G; Mengarelli A; Cudillo L; Maurillo L; Pagano L; Breccia M; Rigacci L; De Fabritiis P
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study.
    Lessi F; Laurino M; Papayannidis C; Vitagliano O; Grimaldi F; Lazzarotto D; Gottardi M; Crisà E; Riva M; Reda G; Ermani M; Semenzato G; Trentin L; Ferrara F
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
    Ragon BK; Daver N; Garcia-Manero G; Ravandi F; Cortes J; Kadia T; Oran B; Ohanian M; Ferrajoli A; Pemmaraju N; Kantarjian HM; Borthakur G
    Am J Hematol; 2017 Sep; 92(9):845-850. PubMed ID: 28494506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan AM; Salimi T; Epstein RS
    Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
    Fathi AT; Erba HP; Lancet JE; Stein EM; Ravandi F; Faderl S; Walter RB; Advani AS; DeAngelo DJ; Kovacsovics TJ; Jillella A; Bixby D; Levy MY; O'Meara MM; Ho PA; Voellinger J; Stein AS
    Blood; 2018 Sep; 132(11):1125-1133. PubMed ID: 30045838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
    Levitz D; Saunthararajah Y; Fedorov K; Shapiro LC; Mantzaris I; Shastri A; Kornblum N; Sica RA; Shah N; Konopleva M; Gritsman K; Braunschweig I; Cooper DL; Pradhan K; Verma A; Feldman EJ; Goldfinger M
    Clin Cancer Res; 2023 Aug; 29(15):2774-2780. PubMed ID: 37341641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
    Sherban A; Raanani P; Gurion R; Wolach O; Gafter-Gvili A
    Leuk Res; 2022 Feb; 113():106773. PubMed ID: 35066294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.